Clinical Trial Technology Editorial

  1. Assessing The Value Of Wearables In Interventional Clinical Trials
    5/24/2018

    Advancements in biosensor technology are becoming increasingly common in the consumer space, with wrists adorned with Fitbits or similar devices, clothing embedded with “intelligent” fibers, and personal safety devices seen in healthcare facilities across the nation. Our culture is increasingly accustomed to tracking health metrics through smartphones and simple recreational wearables. In the pharmaceutical space, we are now seeing where success in the consumer segment can translate to value-adds for clinical trials.

  2. What Does Patient-Centricity Really Mean — And Why Do We Need It?
    5/22/2018

    The challenge to recruit and retain numbers of patients for Phase 3 industry-sponsored trials is not new to the industry. In fact, 48 percent of sites miss their enrollment targets and 80 percent of trials are delayed due to recruitment, but there are new opportunities to achieve recruitment goals while also minimizing dropout. 

  3. Digital R&D: 4 Ways To Maximize Patient Engagement In Clinical Trials
    5/15/2018

    The Deloitte Center for Health Solutions recently interviewed 43 biopharmaceutical industry stakeholders to explore where the industry sees value and opportunities for using digital technologies in the clinical development process; understand reasons behind the relatively slow pace of digital adoption; and uncover strategies to overcome barriers and accelerate the use of digital in clinical trials. This is the first of two articles that shares interview findings and insights published in the new Deloitte Center for Health Solutions report Digital R&D: Transforming the future of clinical development.

  4. Kazia Tries Adaptive Approach For Brain Cancer Trial
    5/14/2018

    Getting drugs to cross the blood-brain barrier can be a challenge for sponsor companies. Kazia Therapeutics is working on a treatment for glioblastoma, the most common and aggressive form of brain cancer. Kazia will use an adaptive approach in a Phase 2 trial using a product which was designed by Genentech to cross the blood-brain barrier.

  5. How Can Disruptive Trial Models Help Us Meet Patients In The Real World?
    5/3/2018

    When it comes to drug development, the pharmaceutical industry has long followed the same model for how we approach clinical trials. However, we are on the precipice of a new opportunity for the entire healthcare system in which emerging technologies can help us develop and deliver medicines to patients in more agile and efficient ways than ever before.

  6. Harnessing The Hype: Can AI And Other Tech Make Patients Better Faster?
    3/22/2018

    Artificial intelligence (AI), blockchain technology, predictive analytics, cloud computing, and speech and image recognition are the latest buzzwords across industries. Numerous companies are looking to inject these technologies into their operations, and a great deal of funding is pouring into related startups.

  7. 3 Keys To Successful Blockchain Adoption In Clinical Research
    3/1/2018

    Excitement around the potential for blockchain platforms continues to build. This parallels the surge in popularity of blockchain-based cryptocurrencies such as Bitcoin. Meanwhile, “critics argue it’s all hype — a technological hammer looking for a nail — and that the complexities of health information prevent practical use of blockchain technology.”

  8. When It Comes To Study Start-Up, The News Is Still Bad
    2/21/2018

    The START II Study, conducted by Tufts CSDD and technology provider goBalto, attempted to determine how bad the study start-up process had become, and how pharma could address the growing problem. It now takes six to seven months on average to perform study start-up. Despite new technologies making the start-up process easier, we still have 11 percent of sites that are never activated.

  9. Will A New Engagement Tool Finally Solve The Patient Recruitment Problem?
    2/14/2018

    Getting new treatments to patients is a long and costly endeavor. Most drugs take upward of eight years and billions of dollars to receive regulatory approval. One of the biggest problems sponsor companies face when trying to launch a Phase 3 trial is finding enough patients to take part in the study.

  10. Focus On Change Management To Aid Technology Adoption
    2/12/2018

    Your employees will always resist technology change. Change tends to bring fear and uncertainty. To overcome fear and make your installation a success, focus on implementation, change management, and providing immediate benefits to users.